Sinopharm Group Co Ltd - H

HKSE:01099 (China)   H
HK$ 21.50 (+3.61%) May 10
8.17
P/B:
0.82
Market Cap:
HK$ 67.09B ($ 8.59B)
Enterprise V:
HK$ 77.88B ($ 9.97B)
Volume:
8.43M
Avg Vol (2M):
6.12M
Also Trade In:
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Sinopharm Group Co Ltd ( HKSE:01099 ) from 2009 to May 11 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Sinopharm Group stock (HKSE:01099) PE ratio as of May 11 2024 is 8.17. More Details

Sinopharm Group Co Ltd (HKSE:01099) PE Ratio (TTM) Chart

To

Sinopharm Group Co Ltd (HKSE:01099) PE Ratio (TTM) Historical Data

Total 1203
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Sinopharm Group PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-05-12 8.2 2024-03-05 10.1
2024-05-10 8.2 2024-03-04 10.6
2024-05-09 7.9 2024-03-01 10.6
2024-05-08 7.9 2024-02-29 10.3
2024-05-07 7.8 2024-02-28 10.3
2024-05-06 7.7 2024-02-27 10.4
2024-05-03 7.5 2024-02-26 10.3
2024-05-02 7.4 2024-02-23 10.5
2024-04-30 7.5 2024-02-22 10.6
2024-04-29 7.7 2024-02-21 10.2
2024-04-26 8.2 2024-02-20 10.2
2024-04-25 8.3 2024-02-19 10.0
2024-04-24 8.2 2024-02-16 10.1
2024-04-23 7.9 2024-02-15 9.7
2024-04-22 8.0 2024-02-14 9.7
2024-04-19 7.6 2024-02-09 9.7
2024-04-18 7.5 2024-02-08 9.9
2024-04-17 7.5 2024-02-07 10.3
2024-04-16 7.4 2024-02-06 10.0
2024-04-15 7.5 2024-02-05 9.6
2024-04-12 7.4 2024-02-02 9.6
2024-04-11 7.5 2024-02-01 9.7
2024-04-10 7.5 2024-01-31 9.6
2024-04-09 7.6 2024-01-30 9.7
2024-04-08 7.5 2024-01-29 9.7
2024-04-05 7.6 2024-01-26 9.4
2024-04-03 7.8 2024-01-25 9.4
2024-04-02 7.7 2024-01-24 8.9
2024-03-28 7.6 2024-01-23 8.7
2024-03-27 9.6 2024-01-22 8.3
2024-03-26 9.4 2024-01-19 8.9
2024-03-25 9.6 2024-01-18 9.1
2024-03-22 9.7 2024-01-17 9.2
2024-03-21 9.8 2024-01-16 9.5
2024-03-20 9.7 2024-01-15 9.7
2024-03-19 9.6 2024-01-12 9.5
2024-03-18 9.8 2024-01-11 9.8
2024-03-15 9.7 2024-01-10 9.6
2024-03-14 9.9 2024-01-09 9.4
2024-03-13 10.0 2024-01-08 9.2
2024-03-12 10.4 2024-01-05 9.3
2024-03-11 10.1 2024-01-04 9.4
2024-03-08 10.0 2024-01-03 9.5
2024-03-07 10.0 2024-01-02 9.5
2024-03-06 10.1 2023-12-29 9.6

Sinopharm Group Co Ltd (HKSE:01099) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2023. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.